The fickle CHO: a review of the causes, implications, and potential alleviation of the CHO cell line instability problem
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Chinese hamster ovary (CHO) cell-based bioproduction of recombinant proteins can now routinely achieve >5 g/L titers in fed-batches. This progress is partly due to the rapid adaptability of CHO cells to various genetic manipulations and changing process conditions. An inherently plastic genome allows for this adaptability; however, it also gives CHO cells the propensity for genomic rearrangements. In combination with the genomic and metabolic demand of high producer cells, CHO cell plasticity manifests itself in the bioproduction process as cell line instability, by way of a decline in productivity and product quality. In this review, we provide a definition for titer and quality stability and discuss the main causes of the CHO instability phenomenon and advances in clone selection and genetic manipulations. We also discuss advances in systems biology efforts that can provide new strategies for early prediction of CHO cell instability, which will help to identify multi-gram per liter titer cell lines that can maintain production stability and reproducible product quality over extended culture durations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032 · cited 1×
“Chinese hamster ovary (CHO) cell lines have been preferentially used to produce recombinant therapeutics and are used for manufacturing approximately 70% of all recombinant biopharmaceutical proteins and for all mAbs (adalimumab, bezlotoxumab, avelumab, dupilumab, durvalumab ocrelizumab, and brodalumab) approved since…”
BackgroundGenome Engineering With Zinc-Finger Nucleases
Carroll, D. (2011) · Genetics · doi:10.1534/genetics.111.131433 · Cited by 1,076
Therapeutic protein aggregation: mechanisms, design, and control
Roberts, C. J. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.05.005 · Cited by 455
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296 · cited 1×
“Chinese hamster ovary (CHO) cell lines have been preferentially used to produce recombinant therapeutics and are used for manufacturing approximately 70% of all recombinant biopharmaceutical proteins and for all mAbs (adalimumab, bezlotoxumab, avelumab, dupilumab, durvalumab ocrelizumab, and brodalumab) approved since…”
BackgroundIsotype and glycoform selection for antibody therapeutics
Jefferis, R. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.03.021 · Cited by 252
Feichtinger, J., Hernández, I., Fischer, C., Hanscho, M., Auer, N., Hackl, M., Jadhav, V., Baumann, M., Krempl, P. M., Schmidl, C., et al. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.25990 · Cited by 148 · cited 1×
“Indeed, histone modification patterns in producer cell lines have been known to continuously undergo modifications leading to gene silencing of the transgene as well as cellular proteins [10,17 ,30].”
BackgroundA reference genome of the Chinese hamster based on a hybrid assembly strategy
Rupp, O., MacDonald, M. L., Li, S., Dhiman, H., Polson, S., Griep, S., Heffner, K., Hernandez, I., Brinkrolf, K., Jadhav, V., et al. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26722 · Cited by 107
Self-citation
Cited by
Liang, K., Luo, H., & Li, Q. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1112349 · Cited by 37
“Recently, monoclonal antibodies (mAbs) and recombinant biopharmaceutical proteins (rBPs) have revolutionized the pharmaceutical industry (Dahodwala and Lee 2019; Zhang et al., 2021).”
BackgroundChitwood, D. G., Wang, Q., Klaubert, S. R., Green, K., Wu, C. H., Harcum, S. W., & Saski, C. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-27962-0 · Cited by 12
From cell clones to recombinant protein product heterogeneity in Chinese hamster ovary cell systems
Wang, C., Guo, X., Wang, W., Li, J.-X., & Wang, T.-Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031324 · Cited by 9
Gurazada, S. G. R., Kennedy, H. M., Braatz, R. D., Mehrman, S. J., Polson, S. W., & Rombel, I. T. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108506 · Cited by 9
Dynamic pH profiles drive higher cell‐specific and volumetric productivity
Klaubert, S. R., Chitwood, D. G., Peng, D., Redman, E., Anderson, J. Y. L., Sandoval, N. R., & Harcum, S. W. (2026) · Biotechnology Progress · doi:10.1002/btpr.70080 · Cited by 3
Metadata
- Authors
- Dahodwala, H., & Lee, K. H.
- Venue
- Current Opinion in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 60
- Pages
- 128-137
- ISSN
- 0958-1669 (ISSN-L)
- OpenAlex
- W2947645884
- Cited by
- 154
- References
- 7
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The fickle CHO: a review of the causes, implications, and potential alleviation of the CHO cell line instability problem. https://app.cochat.ai/papers/10.1016/j.copbio.2019.01.011
- The paper
- Dahodwala, H., & Lee, K. H. (2019). The fickle CHO: a review of the causes, implications, and potential alleviation of the CHO cell line instability problem. Current Opinion in Biotechnology. https://doi.org/10.1016/j.copbio.2019.01.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.